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 Ovarian cancer is aggressive, silent (hidden for the majority of its development) and often 
resistant to cisplatin chemotherapy. Often, each cancer type has unique aneuploidy and gene 
repositioning, but patterns prevail; therefore, the focus of this study is to find the differences in 
patterns between sensitive and resistant ovarian cancer cells.  If cells are resistant to cisplatin 
chemotherapy, then they will have specific gene repositioning and an increase in ploidy.  
Fluorescent In Situ Hybridization (FISH) will be utilized to track repositioning and count 
ploidy on three different ovarian cell lines, two sensitive to cisplatin and one resistant. Twenty-
two different commercially manufactured fluorescent probes will attach to corresponding 
genes in the DNA of the ovarian cell in pairs. Microscopes and software with the help of the 
probes allow visualization of the desired genes in vitro.  Ovarian cancer took 14,000 lives last 
year while the surviving 8,000 had a 75% reoccurrence rate which is often accompanied by 
chemotherapy resistance. Patterns within individual cancers exist and have been used for 
diagnosis and better understanding of the most effective chemotherapy in other cancers.  Ovarian 
cancer is often undiagnosed until it has progressed to an advanced stage. When ovarian cancer 
reaches an advanced stage, 70-80% become resistant to platinum-based chemotherapy, like 
cisplatin. Using FISH to understand if gene repositioning or cell ploidy enables a cell to become 
resistant will make future diagnoses more efficient. If doctors can determine that the cancer will 
be resistant to cisplatin chemotherapy based on the gene count or position, then the patient can 
be redirected to other medication, saving time and increasing chances of survival. Ovarian cancer 
is commonly treated with cisplatin chemotherapy and as ovarian cancer is typically caught very 
late in the progression, any time saved is important.  
